You need to login to view this content. Please . Not a Member? Join Us

November 2, 2021 InvernessPhysician Portal

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). Oral medication Resmetirom administered 80 mg, 100 mg, or matching placebo taken once daily and randomized 1:1:1. Resmetirom is a first-in-class small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist.

Encore logo

As a proven clinical research organization, we take every precaution to assure the safety of and maximize the value for our research volunteers. Qualified doctors, nurses and study coordinators on staff provide support and care throughout the research trial. Participation is always voluntary. We appreciate the time and effort that research volunteers bring to this important process.

Copyright 2021 ENCORE Research Group